Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCeiba Investme. Regulatory News (CBA)

Share Price Information for Ceiba Investme. (CBA)

Share Price is delayed by 15 minutes
Get Live Data
29.00    0.00 (0.00%)
Bid:
24.00
Ask:
34.00
Spread: 10.00 (41.667%)
Market Cap: £47.91m
CBA Live PriceLast checked at - London Stock Exchange

Intraday Ceiba Investme. Share Chart

Statement re Second Amendment of Bond Instrument

13 Feb 2026 17:13

RNS Number : 0184T
Ceiba Investments Limited
13 February 2026
 

STATEMENT RE SECOND AMENDMENT OF BOND INSTRUMENT

CEIBA INVESTMENTS LIMITED

 

(TICKER CBA, ISIN: GG00BFMDJH11)

Legal Entity Identifier: 213800XGY151JV5B1E88

 

SECOND AMENDMENT OF BOND INSTRUMENT (22 MARCH 2021)

 

CEIBA Investments Limited, the largest listed foreign investor solely dedicated to investing in Cuba, announces that today it will circulate to the holders (the "Bondholders") of the €25,000,000 senior, unsecured convertible bonds due 2029 issued by the Company on 21 March 2021, as amended by a first amendment agreement on 24 January 2025 (the "First Amendment Agreement") (the "Bonds") seeking their approval to enter into a second amendment agreement (the "Second Amendment Agreement") to amend the original bond instrument dated 22 March 2021 constituting the Bonds (the "Original Bond Instrument"), as amended by the First Amendment Agreement.

 

The circular ("Circular") to Bondholders and the Second Amendment Agreement are attached to this Announcement and can also be accessed via the Company's website www.ceibainvest.com

http://www.rns-pdf.londonstockexchange.com/rns/0184T_1-2026-2-13.pdf

http://www.rns-pdf.londonstockexchange.com/rns/0184T_2-2026-2-13.pdf

 

In RNS Announcement 7758R of 5 February 2026 we announced that during the month of February 2026, in order to avoid a potential event of default under the terms of the Bond Instrument, the Company would discuss with Bondholders a formal proposal to amend some of the terms of the Bond Instrument, including, inter alia, to: i) extend the term of the Bond Instrument by 12 months by deferring each of the four remaining segments (B, C, D and E) by that additional period; ii) allow the Company to issue new ordinary shares at a price per Share that is less than the latest published NAV (as defined in the Articles of Incorporation of the Issuer) per Share at the time of issuance; and iii) allow the Company to sell part of its assets provided that the proceeds of such issuance or sale are applied towards the repayment of Segment B and other Segments that are due payable under the Bond Instrument.

 

Based on the outcome of these discussions, it would now appear that the required qualified majority of Bondholders support the proposal to amend the terms of the Original Bond Instrument, as amended by the First Amendment Agreement executed 24 January 2025, and approve the Second Amendment Agreement.

 

The final terms contained in the Second Amendment Agreement stipulate that the final payment date is extended to 31 March 2030 and that the Company is authorized to sell assets of the Company and issue new ordinary shares in the capital of the Company at such price as the Board of Directors determines from time to time, even at a discount to the net asset value per share. Following the original expiry date of 31 March 2026, the interest rate on the Bonds will increase to 15%.

 

Today, Bondholders will receive the Circular containing the extraordinary resolutions to be proposed seeking the Bondholders approval of the Company's entry into the Amendment Agreement. In order to be passed successfully, the Extraordinary Resolutions require Bondholders together holding at least 60% of the principal amount of the Bonds in issue to vote in favour of the Extraordinary Resolutions on or before 27 February 2026. Subject to and following the successful passing of the Extraordinary Resolutions the Company will thereafter enter into the Second Amendment Agreement amending the terms of the Original Bond Instrument. 

 

John A. Herring

Chairman

 

 

For further information, please contact:

 

Sebastiaan Berger

 

Via NSM Funds Limited 

Singer Capital Markets 

James Maxwell / Patrick Weaver (Corporate Finance) 

Sam Geatrex (Sales) 

 

 

Tel: +44 (0)20 7496 3000

NSM Funds Limited

Tel: +44 (0)1481 743030

 

 

www.ceibainvest.com 

 

END OF ANNOUNCEMENT

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRGPUQUPUPQGMW
12
Date   Source Headline
5th Jun 20268:33 amRNSTrading Update
27th May 20263:39 pmRNSHolding(s) in Company
22nd May 20262:30 pmRNSHolding(s) in Company
20th May 20263:37 pmRNSHolding(s) in Company
19th May 20261:07 pmRNSHolding(s) in Company
15th May 202612:40 pmRNSDirector/PDMR Shareholding
12th May 20267:00 amRNSIssue of Equity
30th Apr 20267:00 amRNSAnnual Financial Report
14th Apr 20264:46 pmRNSResult of EGM
1st Apr 202611:21 amRNSFurther re Second Amendment of Bond Instrument
27th Feb 20265:14 pmRNSFurther re Second Amendment of Bond Instrument
27th Feb 20262:26 pmRNSDirectorate change
13th Feb 20265:13 pmRNSStatement re Second Amendment of Bond Instrument
13th Feb 20263:20 pmRNSDirector Declaration
12th Feb 20265:32 pmRNSChange of Auditor
5th Feb 20267:00 amRNSTrading Update - Consultation with Bondholders
26th Jan 20263:36 pmRNSDirector/PDMR Shareholding
23rd Dec 20251:39 pmRNSNet Asset Value(s)
4th Dec 20253:25 pmRNSAppointment of Senior Independent Director
2nd Oct 20252:48 pmRNSDirector/PDMR Shareholding
29th Sep 20257:00 amRNSHalf-year Report
12th Sep 20253:16 pmRNSDirectorate Change
8th Jul 20257:00 amRNSTrading Update - Payment to Bondholders
4th Jul 202512:49 pmRNSDirectorate Change
3rd Jul 20253:14 pmRNSResult of AGM
1st Jul 20251:35 pmRNSNet Asset Value(s)
30th Apr 20257:00 amRNSAnnual Financial Report
28th Apr 202510:26 amRNSDirectorate Change
3rd Feb 20257:00 amRNSStatement re Amendment of Bond Instrument
13th Jan 20255:51 pmRNSStatement re Amendment of Bond Instrument
11th Dec 20241:31 pmRNSNet Asset Value(s)
7th Oct 202410:55 amRNSDirector/PDMR Shareholding
7th Oct 20247:00 amRNSStatement re Update from the Chairman
27th Sep 20247:00 amRNSHalf-year Report to 30 June 2024
13th Aug 20248:36 amRNSDirectorate Change
20th Jun 20243:09 pmRNSDirector/PDMR Shareholding
20th Jun 20247:00 amRNSNet Asset Value(s)
18th Jun 20244:53 pmRNSResult of AGM
30th Apr 20247:00 amRNSAnnual Financial Report
25th Mar 202411:03 amRNSDirectorate Change
17th Jan 20247:00 amRNSInvestment Update
27th Dec 20239:17 amRNSNet Asset Value(s)
18th Dec 20238:54 amRNSDirector/PDMR Shareholding
3rd Nov 202310:36 amRNSHolding(s) in Company
1st Nov 20239:05 amRNSDirector/PDMR Shareholding
27th Oct 202311:11 amRNSDirector/PDMR Shareholding
16th Oct 20238:37 amRNSAppointment of Non-Executive Director
12th Oct 20234:26 pmRNSDirector/PDMR Shareholding
5th Oct 202310:24 amRNSDirector/PDMR Shareholding
29th Sep 20237:00 amRNSHalf-year Report
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.